Hip implant under the microscope: tracking the avenir complete stem

NCT ID NCT04731077

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 13, 2026 · Last updated Oct 14, 2026 · Updated 1 time

Summary

Researchers are following people who receive the Avenir Complete femoral stem during hip replacement surgery. The study enrolls adults with advanced hip joint damage from arthritis, injury, or previous failed hip surgery. It tracks how long the implant stays in place, any side effects, and how well patients move and function over time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Avenir Complete femoral stem, a hip replacement implant
What this could lead to
If the implant performs well over time, it could give surgeons and patients more confidence in this option for hip replacement and revision surgery.
What could go wrong
This is a post-market follow-up study, not a randomized trial, so it cannot prove the implant is better than other stems. Some implants may loosen, wear, or need removal, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

275 people

The number who actually took part.

Started

Sep 2021

Expected to finish

Jun 2036

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is at least 20 years old or older and skeletally mature. * Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases; * Failed previous hip surgery including * Joint reconstruction (osteotomy) * Arthrodesis * Hemi-arthroplasty or total hip replacement (THR) * Acute traumatic fracture of the femoral head or neck; * Avascular necrosis of the femoral head. * Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study; Exclusion Criteria: * Acute, chronic, local, or systemic infections; * Severe muscular, neural, or vascular diseases that endanger the limbs involved; * Lack of bony structures proximal or distal to the joint, so that good Inclusion criteria * Patient is at least 20 years old or older and skeletally mature. * Advanced wear of the joint due to degenerative, post-traumatic or rheumatic diseases; * Failed previous hip surgery including * Joint reconstruction (osteotomy) * Arthrodesis * Hemi-arthroplasty or total hip replacement (THR) * Acute traumatic fracture of the femoral head or neck; * Avascular necrosis of the femoral head. * Patients capable of understanding the surgeon's explanations and following his instructions, able and willing to participate in the follow-up program and who gave consent to take part in the study; Exclusion criteria * Acute, chronic, local, or systemic infections; * Severe muscular, neural, or vascular diseases that endanger the limbs involved; * Lack of bony structures proximal or distal to the joint, so that good anchorage of the implant is unlikely or impossible; * Total or partial absence of the muscular or ligamentous apparatus; * Any concomitant diseases that can jeopardize the functioning and the success of the implant; * Allergy to the implanted material, especially to metal (e.g. cobalt, chromium, nickel, etc.); * Local bone tumors and/or cysts; * Pregnancy; * Skeletal immaturity. * Patients unwilling or unable to give consent, or to comply with the follow-up program; * Patients who have any condition that would - in the judgement of the Investigator - place him/her at undue risk or * interfere with the study; * Any vulnerable subject: * a prisoner * mentally incompetent or unable to understand what participation in the study entails * a known alcohol or drug abuser * anticipated to be non-compliant * Patients with plans to relocate during the study follow-up period; * Individuals whose willingness to volunteer in a clinical investigation could be unduly influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Avascular necrosis of hip are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Copenhagen University Hospital, Hvidovre

    Copenhagen, DK-2650, Denmark

  • Heartland Regional Medical Center d.b.a. Mosaic Life Care

    Saint Joseph, Missouri, 64506, United States

  • Ikazia Ziekenhuis

    Rotterdam, South Holland, 3083 AN, Netherlands

  • Mississippi Sports Medicine and Orthopaedic Center PLLC

    Jackson, Mississippi, 39202, United States

  • Nissan Tamagawa Hospital

    Setagaya-Ku, Tokyo, 410-0302, Japan

  • Okayama City Hospital

    Okayama, 700-0962, Japan

  • Orthopedic & Fracture Clinic, PC

    Portland, Oregon, 97225, United States

  • Sahlgrenska University Hospital - Molndal

    Mölndal, 43180, Sweden

  • Sykehuset Innlandet HF

    Tynset, 2500, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.